

"Great Ideas Originate in the Muscles" – Thomas Edison

Corporate Overview

MYOS is an emerging Bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function.

MYOS is the owner of Fortetropin[®], the natural food product clinically shown to increase lean muscle size and mass in conjunction with resistance training. Fortetropin[®] is a fertilized egg yolk-based product, manufactured via a proprietary process to retain its biological activity, which MYOS believes has the potential to redefine existing standards for muscle health.

Fortetropin[®]: Our Proprietary, Advanced Nutrition Product

- Fertilized egg yolk powder produced via patented technology developed by German Institute of Food Technology/DIL
- Issued method of manufacturing patent providing coverage through 2033
- Increases muscle size, lean body mass
- Fortetropin[®] is manufactured in modern state-of-the-art GMP facilities utilizing advanced technologies and high standards of quality
- Extremely high safety profile; "100,000 years of human safety history"
- Reduces free serum myostatin levels


MYOS Quick Facts

Trading Symbol:	MYOS (NASDAQ CM)
Price as of 6/15/18:	\$1.55
52 Week High-Low	\$2.38 - \$1.03
Avg Volume (50 Days)	51,167
Shares Outstanding:	7.47 million (5/9/18)
Fiscal Year End:	December 31
Auditors:	WithumSmith+Brown, PC
IR Counsel:	Porter, LeVay & Rose, Inc.
Contact:	Michael Porter
Email:	MYOS@plrinvest.com


Why Invest in MYOS?

- Science-based company focused on musculoskeletal health
- Poised to capitalize on global sports nutrition market expected to reach \$45B (2022) as well as the nearly \$600m US veterinary supplement market
- Proprietary Fortetropin[®] with clinical data demonstrating ability to enhance muscle size and mass
- Product portfolio targeting fitness, domestic pet market, functional and medical foods and age management
- IP strategy to provide commercial protection of Fortetropin[®] and related discoveries through 2033 and beyond
- Management team dedicated to prudent cost management – reduced quarterly cash burn

Fortetropin[®]: Enhancing Muscle Size and Muscle Health



Fortetropin[®] Increases Muscle Size and Mass in Conjunction with Resistance Training¹



¹Sharp, Matthew H., et al. *Journal of the American College of Nutrition* 35.8 (2016): 679-691.

Robust Product Portfolio

Qurr – Muscle Health, Muscle Growth

Qurr Strong, for athletes hoping to reach their most ambitious training goals

Qurr Toned, for promoting healthy muscle which can lead to a beautiful lean and toned body

Qurr Well, which supports healthy aging by increasing lean muscle



Yolked™ – for Competitive Athletes



- Yolked™ received Certified for Sport® certification from NSF in April 2018
- NSF Recognized by NFL, MLB, PGA and LPGA
- Sets the stage for discussions with collegiate and professional athletic programs



NSF International
Certified for Sport®

MYOS Canine Muscle Formula



- The ONLY pet health supplement product that addresses muscle atrophy, supports muscle health in dogs, featuring Fortetropin® as the active ingredient
- Comes in powder form and is formulated to mix well with and fortify a dog's existing food of choice
- Available for dogs of all sizes – a single canister provides approximately 60 servings/ two-month supply of product for a medium-sized dog
- Distributed through established veterinary practices and online at www.mypet.com



Ongoing Research Partnerships



Effect of Fortetropin® on Skeletal Muscle Protein Fractional Synthetic Rate in Older Men and Women

Evaluation of Fortetropin® to Reverse Disuse Muscle Atrophy in Dogs After Orthopedic Surgery to Repair Ruptured Cranial Cruciate Ligament

Research Program Focused on Discovery of Compounds for Promoting the Growth and Development of Muscle Tissue

Studying the efficacy of Fortetropin® in preventing weight and muscle loss associated with cancer in a mouse model of lung cancer

Mid-Term Opportunities

Medical Foods - For Dietary Management of:

Sarcopenia

- Age-related muscle loss
- Affects >20M age 60+
- Planned clinical study to measure impact of Fortetropin® on rate of muscle synthesis in 60+ adults

Cachexia

- Serious wasting condition associated with cancer, COPD, CKD, etc.
- >5M individuals cachexic chronic diseases

Recovery & Rehabilitation

- Muscle atrophy from immobilization is a major problem after knee surgery
- Positive results from our dog study would provide rationale to initiate clinical study evaluating impact of Fortetropin® on recovery after ACL surgery

Long-Term Opportunities

Biotherapeutics:

- Active moieties in Fortetropin®
- Potential acquisition of complementary technologies

Experienced Scientific Advisors & Board of Directors

Scientific Advisory Board	Affiliations
Robert J. Hariri, M.D., Ph.D.	Celgene, Cornell University, Human Longevity, Inc., Celularity
Louis Aronne, M.D.	American College of Physicians, Weill-Cornell Medical College, Obesity Society, Columbia University
Neilank Jha, M.D.	KONKUSSION, Toronto Western Hospital, University of Toronto, McMaster University
Caroline Apovian, M.D.	Boston University School of Medicine, Boston Medical Center, Obesity Society

Board of Directors	Affiliations
Robert J. Hariri, M.D., Ph.D.	Celgene, Cornell University, Human Longevity, Inc., Celularity
Ren Ren	RENS Agriculture Science and Technology Co, Ltd
Louis Aronne, M.D.	American College of Physicians, Weill-Cornell Medical College, Obesity Society, Columbia University
Bin Zhou, J.D.	Bernard & Yam, LLP
John Nosta	NOSTALAB, Ogilvy CommonHealth
Victor Mandel	Criterion Capital Management, LLC, Ambac Financial Group, Inc., Goldman Sachs
Chris Pechock	Matlin Patterson, Credit Suisse, Eos Partners, Paine Webber, Gleacher & Company
Joseph Mannello	BNY Mellon, Gleacher & Company, Brean Capital, LLC

Recent News Events

[June 6, 2018 – Launches Advanced Veterinary Supplement Product For Dogs, Powered By Fortetropin®](#)

[April 10, 2018 – Introduces New Sports Nutrition Product Line, Yolked™, and Earns Prestigious "Certified For Sport®" Certification From NSF International](#)

[March 27, 2018 – Announces Research Agreement with Rutgers University Focused on Discovery of Compounds and Products for Improving Muscle Health and Performance](#)

[March 27, 2018 – Reports Fourth Quarter and FY 2017 Results - Revenue Increased 61% Over Prior Year; Gross Profit Margin of 41%](#)

[December 6, 2017 – Enters into Research Agreement with University of California, Berkeley to Study Effects of Fortetropin® on Skeletal Muscle Protein Synthetic Rate in Older Men and Women](#)

[November 14, 2017 – Reports Third Quarter 2017 Financial Results - Revenue Increased 312% over prior year; Gross Profit Margin of 59%](#)

[November 8, 2017 – Launches Collegiate Sports Marketing Platform with IMG College, a Division of Leading Sports and Marketing Agency IMG](#)

[October 26, 2017 – Pro Football Legends, the Commercial Marketing Arm of the NFL Alumni, Launches Partnership with MYOS RENS Technology Inc. in Optimal Bowl and Wellness Challenge](#)

Any statements in this document that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including Querr® products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.